Clearside Biomedical (NSDQ:CLSD) said today it will redirect its R&D efforts from its pre-clinical axitinib wet age-related macular degeneration therapy to its Zuprata diabetic macular edema treatment.
The Alpharetta, Ga.-based company said that recent trial results from other companies investigating combination therapies for wet AMD have led Clearside to reconsider its proprietary suspension formulation of axitinib. The company selected axitinib in mid-2016 for the treatment of wet AMD through suprachoroidal administration.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside bails on AMD, all-in on diabetic macular edema appeared first on MassDevice.
from MassDevice http://ift.tt/2lMD89j
Cap comentari:
Publica un comentari a l'entrada